Randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma: The final analysis of cohort 1.

被引：0
|
作者：
Seedor, Rino S.
Orloff, Marlana M.
Sharpe-Mills, Erin
Hulse, Liam
Shelat, Reshma
Shimada, Ayako
Chervoneva, Inna
Shields, Carol L.
Shields, Jerry A.
Mastrangelo, Michael J.
Sato, Takami
机构：
[1] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA
[2] Wills Eye Hosp & Res Inst, Oncol Serv, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9586
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial
    Hersey, P
    Coates, AS
    McCarthy, WH
    Thompson, JF
    Sillar, RW
    McLeod, R
    Gill, PG
    Coventry, BJ
    McMullen, A
    Dillon, H
    Simes, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4181 - 4190
  • [22] Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers
    George, Daniel J.
    Martini, Jean-Francois
    Chang, Yen-Hwa
    Staehler, Michael
    Breza, Jan
    Patard, Jean-Jacques
    Motzer, Robert J.
    Magheli, Ahmed
    Escudier, Bernard
    Carteni, Giacomo
    Gerletti, Paola
    Li, Sherry
    Casey, Michelle
    Laguerre, Brigitte
    Pandha, Hardev S.
    Pantuck, Allan J.
    Patel, Anup
    Lechuga, Maria
    Ravaud, Alain
    CANCER RESEARCH, 2017, 77
  • [23] Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients
    Nikhil Kumar
    Mithalesh Kumar Singh
    Lata Singh
    Neiwete Lomi
    Rachna Meel
    Neelam Pushker
    Seema Sen
    Seema Kashyap
    Human Cell, 2023, 36 : 342 - 352
  • [24] KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
    Luke, Jason J.
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Gershenwald, Jeffrey E.
    Grob, Jean-Jacques
    Hauschild, Axel
    Kirkwood, John M.
    Long, Georgina, V
    Mohr, Peter
    Robert, Caroline
    Ross, Merrick
    Scolyer, Richard A.
    Yoon, Charles H.
    Poklepovic, Andrew
    Rutkowski, Piotr
    Anderson, James R.
    Ahsan, Sama
    Ibrahim, Nageatte
    Eggermont, Alexander M. M.
    FUTURE ONCOLOGY, 2020, 16 (03) : 4429 - 4438
  • [25] Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients
    Kumar, Nikhil
    Singh, Mithalesh Kumar
    Singh, Lata
    Lomi, Neiwete
    Meel, Rachna
    Pushker, Neelam
    Sen, Seema
    Kashyap, Seema
    HUMAN CELL, 2023, 36 (01) : 342 - 352
  • [26] MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients
    Marshall, Ernie
    Romaniuk, Christopher
    Ghaneh, Paula
    Wong, Helen
    McKay, Marie
    Chopra, Mona
    Coupland, Sarah E.
    Damato, Bertil E.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2013, 97 (02) : 159 - 163
  • [27] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
    Mao, Lili
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Li, Siming
    Tang, Bixia
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
  • [28] Real-Life Cohort of Patients With Resected High-Risk Melanoma Treated by Adjuvant Anti-PD1 Therapy
    Benzoni, Liza
    Eberhardt, Anais
    Milley, Sarah
    Idoudi, Safa
    Trefcon, Camille
    Romain-Scelle, Nicolas
    Thomas, Luc
    Dalle, Stephane
    CANCER MEDICINE, 2025, 14 (06):
  • [29] EPIGENETIC THERAPY WITH S-AZACITIDINE, VALPROIC ACID, AND ATRA IN PATIENTS WITH HIGH-RISK AML OR MDS: RESULTS OF THE FRENCH VIVEDEP PHASE II STUDY
    Raffoux, E.
    Recher, C.
    Gardin, C.
    Marolleau, J. P.
    Reman, O.
    Cras, A.
    Turlure, P.
    Maury, S.
    De Labarthe, A.
    Degos, L.
    Chevret, S.
    Chomienne, C.
    Dombret, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 303 - 303
  • [30] Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study
    Raffoux, Emmanuel
    de Labarthe, Adrienne
    Cras, Audrey
    Recher, Christian
    Turlure, Pascal
    Marolleau, Jean-Pierre
    Reman, Oumedaly
    Gardin, Claude
    Maury, Sebastien
    Rousselot, Philippe
    Malfuson, Jean-Valere
    Maarek, Odile
    Degos, Laurent
    Chomienne, Christine
    Dombret, Herve
    BLOOD, 2008, 112 (11) : 283 - 283
12345